Cancer mortality: debunking the 97% myth and the $291 billion industry

The 97% cancer mortality claim: a flawed statistic and a booming business

A study presented in 2025 counted 83,000 medical oncologists worldwide, registered in 105 countries. Global data for 2024 reported 20.6 million new cancer cases and 9.8 million deaths. This represents a mortality rate of 47.5%, not the 97% claimed by viral narratives. However, this populist figure has merit: it has sparked conversation about what mainstream oncology often overlooks.

The math behind the 97%: a healthy hoax

The 97% figure is simply false. If every oncologist lost 97% of their patients, they would either be institutionalized or unemployed. Survival rates have improved significantly for certain tumors, but that doesn't sell products or fill pharmaceutical coffers. The market reality is different: $291 billion in oncology drugs. That is the core issue. The business is so vast that the falsity of the 97% claim becomes irrelevant.

The 2024 data is stubborn: 20.6 million new cases, 9.8 million deaths. Nearly half, not 97%. Yet, the perception that chemotherapy is a "scheduled death" persists. Some argue that conventional medicine has no interest in curing, only in chronicling disease. Others, more pragmatic, point out that spontaneous remission exists but is hidden.

Spontaneous remission: the elephant in the clinic

The reference work is by Zahl, Maehlen, and Welch, published in 2008 in Archives of Internal Medicine. They examined 119,472 Norwegian women aged 50 to 64. One group underwent three biennial mammograms between 1996 and 2001; the other had one at the end of those six years. The logic is clear: if no tumors disappeared on their own, both groups should have ended with the same cumulative number of cases. This was not the case. The conclusion: some breast cancers detected via screening would never have caused symptoms.

There is more. Bell et al. reviewed 29 autopsy studies from over twenty countries in 2015, all involving men who died from other causes. Undiagnosed prostate cancer during life: around 5% under age thirty, rising with age to nearly 59% above seventy-nine. In other words, six out of ten elderly men die with prostate cancer without knowing it. Tumors that remit alone, go undetected because they disappear, and therefore cannot have reliable statistics.

The cancer business and alternative therapies

With $291 billion at stake, resistance to any therapy outside standard protocols is understandable. The case of Simoncini, an Italian oncologist who advocated intratumoral sodium bicarbonate, is paradigmatic. He was persecuted and lost his license. His hypothesis, based on tumor microenvironment acidity, was ridiculed. But in 2021, researchers at the Technion in Israel, led by Dr. Hanan Abumanhal Masarweh, developed sodium bicarbonate nanoparticles that modify tumor acidity and increase permeability to chemotherapy drugs. It is not a cure, but it validates part of the intuition.

Steve Jobs' anecdote illustrates the complexity: diagnosed in 2003 with a neuroendocrine pancreatic tumor, he lived eight years. Conventional medicine gave him months. It was not a miracle, but the difference between an aggressive and an indolent tumor. However, the line between miracle and science is thin.

The myth of Asclepius and the open ending

Business was business even in Olympus. Asclepius, the Greek god of medicine, cured and resurrected everyone. No one died. Hades, king of the underworld, complained to Zeus, who killed Asclepius. The sarracena is uncomfortable: if total healing existed, the system would collapse. Today, the discussion stalls due to lack of consensus on alternative therapies and the weight of the industry. Meanwhile, the data remains: 47.5% mortality, not 97%. And a $291 billion market that isn't going away.